Comparing clinical outcomes between patients with urothelial carcinoma who treated neoadjuvant chemotherapy by gemcitabine-cisplatin and dose dense MVAC.

被引：0
|
作者：
Lee, Yongjune
Kim, Young Seok
Hong, Bumsik
Cho, Yong Mee
Lee, Jae-Lyun
机构：
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Internal Med, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiat Oncol, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Urol, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul, South Korea
[5] Asan Med Ctr, Seoul, South Korea
[6] Univ Ulsan, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.376
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
376
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Early outcomes with neoadjuvant high-dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (HD-MVAC) or gemcitabine and cisplatin (GC) in muscle-invasive urothelial carcinoma of the bladder: A single-institution experience.
    Mitra, N.
    Monk, J. P.
    Pohar, K. S.
    Shabsigh, A.
    Sharp, D. S.
    Abaza, R.
    Box, G. N.
    Zynger, D. L.
    Vandlik, S. L.
    Bhinder, A. S.
    Olencki, T.
    Bahnson, R. R.
    Clinton, S. K.
    Mortazavi, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] Radiographic predictors of pathologic response to neoadjuvant chemotherapy with gemcitabine and cisplatin in patients with high-grade upper tract urothelial carcinoma
    Wong, Nathan Colin
    Ghafoor, Soleen
    Vargas, Hebert Alberto
    Bajorin, Dean F.
    Coleman, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [23] Efficacy and tolerability of biweekly gemcitabine plus cisplatin (GEMCIS) or gemcitabine plus paclitaxel (GEMPAC) as neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder
    Karaoglu, Aziz
    Nieh, Peter
    Canter, Daniel
    Master, Viraj A.
    Carthon, Bradley
    Harris, Wayne
    Shelton, Joseph
    Rossi, Peter John
    Jani, Ashesh B.
    Khan, Mohammad K.
    Osunkoya, Adeboya O.
    Ogan, Ken
    Pattaras, John
    Ritenour, Chad
    Kucuk, Omer
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma
    Miyake, Makito
    Shimizu, Takuto
    Nishimura, Nobutaka
    Kiba, Keisuke
    Maesaka, Fumisato
    Oda, Yuki
    Tachibana, Akira
    Tomizawa, Mitsuru
    Ohmori, Chihiro
    Matsumura, Yoshiaki
    Ichikawa, Kazuki
    Mizobuchi, Shinichiro
    Yoshikawa, Takanosuke
    Hori, Shunta
    Morizawa, Yosuke
    Gotoh, Daisuke
    Nakai, Yasushi
    Anai, Satoshi
    Torimoto, Kazumasa
    Aoki, Katsuya
    Tanaka, Nobumichi
    Fujimoto, Kiyohide
    CLINICAL GENITOURINARY CANCER, 2022, 20 (02) : 196.e1 - 196.e9
  • [25] Correlation of DNA damage response (DDR) gene alterations with response to neoadjuvant (neo) dose-dense gemcitabine and cisplatin (ddGC) in urothelial carcinoma (UC).
    Iyer, Gopa
    Balar, Arjun Vasant
    Milowsky, Matthew I.
    Huang, William C.
    Woods, Michael
    Donat, S. Machele
    Herr, Harry W.
    Dalbagni, Guido
    Bochner, Bernard H.
    Ostrovnaya, Irina
    Al-Ahmadie, Hikmat
    Rose, Tracy Lynn
    Riches, Jamie Cathleen
    Kania, Brooke Elizabeth
    Boyd, Marie Elena
    Regazzi, Ashley Marie
    McCoy, Asia S.
    Drier, Anthony
    Rosenberg, Jonathan E.
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] Phase II study of neoadjuvant chemotherapy with 4 cycles of dose dense MVAC followed by radical surgery in Korean patients with MIBC and locally advanced urothelial carcinoma of bladder (NCT04047693)
    Park, K.
    Nam, J. K.
    Lee, H. J.
    Kim, T. U.
    Ryu, H.
    Ki, Y. K.
    Kim, J-J.
    Oh, S. B.
    Oh, S. Y.
    Hong, Y. J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1335 - S1335
  • [27] Phase II study of neoadjuvant chemotherapy with four cycles of dose-dense MVAC followed by radical cystectomy in Korean patients with muscle-invasive or locally advanced urothelial carcinoma of bladder
    Park, Kwonoh
    Lee, Hyun Jung
    Kim, Tae Un
    Ryu, Hwaseong
    Ki, Yong Kan
    Hong, Yun Jeong
    Nam, Jong Kil
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 (06) : 739 - 746
  • [28] Outcomes of Palliative Weekly Low-Dose Gemcitabine-Cisplatin Chemotherapy in Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer Patients
    Kim, Jung Sun
    Park, In Hae
    Lee, Keun Seok
    Ro, Jungsil
    JOURNAL OF BREAST CANCER, 2014, 17 (04) : 339 - 343
  • [29] Institutional retrospective review of presurgical cisplatin-based chemotherapy (chemo) in patients with urothelial carcinoma (UC): Gemcitabine plus cisplatin (GC) versus dose-dense methotrexate, vinblastine, doxorubicin, cisplatin (ddMVAC)
    Harshman, Lauren Christine
    Jacobus, Susanna J.
    Mullane, Stephanie A.
    Feldman, Hope
    Hirsch, Michelle S.
    Kantoff, Philip W.
    Choueiri, Toni K.
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [30] Combination of Gemcitabine and Paclitaxel is a Favorable Option for Patients with Advanced or Metastatic Urothelial Carcinoma Previously Treated with Cisplatin-based Chemotherapy
    Ikeda, Masaomi
    Matsumoto, Kazumasa
    Tabata, Ken-ichi
    Minamida, Satoru
    Fujita, Tetsuo
    Satoh, Takefumi
    Iwamura, Masatsugu
    Baba, Shiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (10) : 1214 - 1220
12345